Free Trial
NASDAQ:OLMA

Olema Pharmaceuticals Q2 2025 Earnings Report

Olema Pharmaceuticals logo
$5.46 -0.06 (-1.09%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$5.44 -0.02 (-0.37%)
As of 08/29/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Olema Pharmaceuticals EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Olema Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Olema Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, August 11, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Olema Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025

Olema Pharmaceuticals Earnings Headlines

Warren Buffett Issues Cryptic Warning on U.S. Dollar
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
See More Olema Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Olema Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Olema Pharmaceuticals and other key companies, straight to your email.

About Olema Pharmaceuticals

Olema Pharmaceuticals (NASDAQ:OLMA), a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

View Olema Pharmaceuticals Profile

More Earnings Resources from MarketBeat